Alembic Pharmaceuticals Limited ( the Resulting C ompany ) was
on 16th June, 2010 in the name and style 'Alembic Pharma Limited',
under the Companies
Act, 1956 and had received the Certificate of Commencement of
business on 1st July, 2010.
The company changed its name from Alembic Pharma Limited to Alembic
Limited and the Registrar of Companies, Gujarat has approved the
change of name and
issued a fresh certificate of incorporation consequent upon change of
name on 12th March,
Alembic and Breckenridge Announce Paragraph IV ANDA Litigation with
Pfizer on Desvenlafaxine (Pristiq®).
Alembic Pharmaceuticals Limited enters into a product development and
license agreement with Accu-Break Pharmaceuticals, Inc, USA.
-Alembic gets USFDA approval for its NDA - Desvenlafaxine Base
Extended Release Tablets and also entered into an out-licensing
agreement with Ranbaxy Pharmaceuticals Inc (Ranbaxy) to market its
product in USA.
-Alembic announces joint venture with Adwiya Mami SARL Algeria
through its wholly owned Subsidiary - Alembic Global Holding S.A..
-Alembic Pharmaceuticals Ltd. arm signs exclusive agreement with